Abstract 056: Serum Metabolomic Profile of the Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern

Circulation ◽  
2018 ◽  
Vol 137 (suppl_1) ◽  
Author(s):  
Casey M Rebholz ◽  
Alice H Lichtenstein ◽  
Zihe Zheng ◽  
Lawrence J Appel ◽  
Josef Coresh
Keyword(s):  
Dietary Pattern ◽  
Control Diet ◽  
Area Under The Curve ◽  
Serum Levels ◽  
Dash Diet ◽  
Randomized Controlled ◽  
Metabolomic Profiling ◽  
C Statistic ◽  
Broad Array ◽  
And Control

Introduction: The DASH dietary pattern emphasizes vegetables, fruits, and low-fat dairy products and is associated with improved cardiometabolic outcomes. No biomarkers exist for assessing adherence to this dietary pattern. The objective of the study was to use metabolomics to identify serum compounds associated with the DASH diet. Methods: We conducted untargeted metabolomic profiling in stored serum specimens collected from participants at the end of an 8-week multi-center, randomized, controlled feeding study (N=218) comparing the DASH diet to a diet typical of intake in the U.S. (control). Multivariable linear regression was used to compare the association of individual log-transformed metabolites between the two diets after adjusting for age, sex, race, education, body mass index, and hypertension. Partial least squares-discriminant analysis was used to identify a composite of compounds that discriminate between the DASH and control diets. The area under the curve was calculated as the cumulative ability to distinguish between diets. Results: Serum levels of 97 known metabolites were significantly different among participants randomized to the DASH diet compared to the control diet at the Bonferroni threshold (p<6.11x10 -5 ; Figure ). The majority of these 97 metabolites were lipids (n=64; 66.0%), followed by amino acids (n=15), xenobiotics including food components (n=10), cofactors and vitamins (n=6), carbohydrate (n=1), and nucleotide (n=1). The ten most influential metabolites for discriminating between the DASH and control diets were: N-methylproline, stachydrine, tryptophan betaine, theobromine, 7-methylurate, chiro-inositol, 3-methylxanthine, methyl glucopyranoside, β-cryptoxanthin, and 7-methylxanthine (C statistic=0.986). Conclusion: An untargeted metabolomic platform identified a broad array of serum metabolites that differed between the DASH and control dietary patterns. The composite of top ten metabolites may be used to assess adherence to the DASH dietary pattern.

scholarly journals Serum untargeted metabolomic profile of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern

2018 ◽  
Vol 108 (2) ◽  
pp. 243-255 ◽  
Author(s):  
Casey M Rebholz ◽  
Alice H Lichtenstein ◽  
Zihe Zheng ◽  
Lawrence J Appel ◽  
Josef Coresh
Keyword(s):  
Dietary Patterns ◽  
Dietary Pattern ◽  
Disease Risk ◽  
Control Diet ◽  
Cardiovascular Disease Risk ◽  
Area Under The Curve ◽  
Fruit And Vegetables ◽  
Dash Diet ◽  
C Statistic ◽  
Broad Array

ABSTRACT Background The Dietary Approaches to Stop Hypertension (DASH) dietary pattern is recommended for cardiovascular disease risk reduction. Assessment of dietary intake has been limited to subjective measures and a few biomarkers from 24-h urine collections. Objective The aim of the study was to use metabolomics to identify serum compounds that are associated with adherence to the DASH dietary pattern. Design We conducted untargeted metabolomic profiling in serum specimens collected at the end of 8 wk following the DASH diet (n = 110), the fruit and vegetables diet (n = 111), or a control diet (n = 108) in a multicenter, randomized clinical feeding study (n = 329). Multivariable linear regression was used to determine the associations between the randomized diets and individual log-transformed metabolites after adjustment for age, sex, race, education, body mass index, and hypertension. Partial least-squares discriminant analysis (PLS-DA) was used to identify a panel of compounds that discriminated between the dietary patterns. The area under the curve (C statistic) was calculated as the cumulative ability to distinguish between dietary patterns. We accounted for multiple comparisons with the use of the Bonferroni method (0.05 of 818 metabolites = 6.11 × 10−5). Results Serum concentrations of 44 known metabolites differed significantly between participants randomly assigned to the DASH diet compared with both the control diet and the fruit and vegetables diet, which included an amino acid, 2 cofactors and vitamins (n = 2), and lipids (n = 41). With the use of PLS-DA, component 1 explained 29.4% of the variance and component 2 explained 12.6% of the variance. The 10 most influential metabolites for discriminating between the DASH and control dietary patterns were N-methylproline, stachydrine, tryptophan betaine, theobromine, 7-methylurate, chiro-inositol, 3-methylxanthine, methyl glucopyranoside, β-cryptoxanthin, and 7-methylxanthine (C statistic = 0.986). Conclusions An untargeted metabolomic platform identified a broad array of serum metabolites that differed between the DASH diet and 2 other dietary patterns. This newly identified metabolite panel may be used to assess adherence to the DASH dietary pattern. This trial was registered at http://www.clinicaltrials.gov as NCT03403166.

Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
C Filippou ◽  
C Thomopoulos ◽  
C Mihas ◽  
K Dimitriadis ◽  
L Sotiropoulou ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trials ◽  
Dietary Intervention ◽  
Sodium Intake ◽  
Meta Analysis ◽  
Control Diet ◽  
Blood Pressure Reduction ◽  
Controlled Trials ◽  
Dash Diet ◽  
Randomized Controlled

Abstract Background The dietary approaches to stop hypertension (DASH) diet is recognized as an effective dietary intervention to reduce blood pressure (BP). However, among randomized controlled trials (RCTs) investigating the DASH diet mediated BP reduction,there are significant methodological and clinical differences. Purpose The purpose of this study was to comprehensively assess the effect of the DASH diet on BP levels in adults with and without hypertension, accounting for underlying methodological and clinical confounders. Methods We systematically searched Medline and the Cochrane Collaboration Library databases and identified 30 RCTs (n=5,545 participants) that investigated the BP effects of the DASH diet compared to a control diet in hypertensive and non-hypertensive adults. Both random-effects and fixed-effect models were used to calculate the mean attained systolic BP (SBP) and diastolic BP (DBP) differences during follow-up. Subgroup and meta-regression analyses were also conducted. Results The DASH diet reduced SBP and DBP significantly more compared to the control diet (difference in means: −3.2 mm Hg; 95% CI: −4.2, −2.3; P&lt;0.001, and −2.5 mm Hg; 95% CI: −3.5, −1.5; P&lt;0.001, respectively). Hypertension status did not modify the effect on BP reduction. The DASH diet compared to the control diet reduced SBP levels to a higher extent in trials with sodium intake &gt;2,400 mg/day compared to trials with sodium intake ≤2,400 mg/day, while both SBP and DBP were reducedmore in trials with mean age &lt;50 years compared to trials of older participants. The quality of evidence was rated as moderate forboth outcomes according to the Grading of Recommendations, Assessment, Development and Evaluation approach. Conclusion The adoption of the DASH diet was accompanied by significant BP reduction in adults with and without hypertension, while higher daily sodium intake and younger age enhanced the BP-lowering effect of the intervention. This meta-analysis was registered in the International Prospective Register of Systematic Reviews as CRD42019128120. Funding Acknowledgement Type of funding source: None

scholarly journals Effect of Time-Restricted Feeding on Body Weight and Cardiometabolic Risks: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A8-A9
Author(s):  
Darin Ruanpeng ◽  
Sikarin Upala ◽  
Anawin Sanguankeo
Keyword(s):  
Systematic Review ◽  
Weight Loss ◽  
Fat Mass ◽  
Lean Mass ◽  
Meta Analysis ◽  
Control Diet ◽  
Intermittent Fasting ◽  
Randomized Controlled ◽  
Total Fat ◽  
And Control

Abstract Introduction: Time-restricted eating (TRE) or time-restricted feeding (TRF), a form of intermittent fasting (IF) when food consumption is restricted to a 4–12 hour window, poses unique possible health benefits that allow the nutrient to work in harmony with circadian rhythm. Whether TRF is effective in weight loss and cardiometabolic profile compare to usual diet is controversial. We conducted a meta-analysis of randomized control trials to investigate the weight and metabolic effects of TRF in humans. Methods: The systematic review was conducted according to the PRISMA guidelines. The literature search was conducted in MEDLINE, EMBASE, and CENTRAL from database inception to November 30, 2020. The search terms included time restricting feeding, time-restricted eating, periodic fasting, intermittent fasting, and periodic fasting. The eligibility criteria included a randomized controlled trial (RCT) comparing the effect of TRF as an intervention and control diet on weight and cardiometabolic risks in individuals with overweight (BMI 23–26.9 kg/m2 in Asian and 25–29.9 kg/m2 in others) or obesity (BMI≥27 kg/m2 in Asian and ≥30 kg/m2 in others) with study duration of at least 8 weeks. The primary outcome is the change in body weight between preintervention and postintervention. The secondary outcome is the change in total fat mass and lean mass, HDL, LDL, and triglycerides. Pool mean differences (MD) with 95% confidence interval (CI) were calculated for each outcome. Results: Four articles met the inclusion criteria and were included in this systematic review and meta-analysis. There were 511 participants with BMI 24 kg/m2 and above and aged between 18 and 65. TRF was defined as a 4–8 hours ad-lib unrestricted eating in 24 hours. The control diet was defined as ad-lib eating per usual habits. There was a significant improvement in weight and body composition in the TRF group. The mean weight loss was -2.08 kg (95% CI: -3.49 to -0.68) greater among TRF group. There was a significant total fat mass and lean mass loss in the TRF group with the MD of -1.29 kg (95% CI: -2.04 to -0.54) and -0.59 kg (95% CI: -1.15 to -0.03), respectively. There was no significant change in HDL, LDL, or triglycerides comparing between TRF and control diet. Conclusion: This systematic review and meta-analysis of RCT showed that TRF with no calories restriction resulted in significant decreased in weight, fat mass, and a slight decreased in total lean mass compared with control diet. Our findings support TRF as an effective lifestyle intervention for weight loss.

scholarly journals Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 11 (5) ◽  
pp. 1150-1160 ◽  
Author(s):  
Christina D Filippou ◽  
Costas P Tsioufis ◽  
Costas G Thomopoulos ◽  
Costas C Mihas ◽  
Kyriakos S Dimitriadis ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trials ◽  
Dietary Intervention ◽  
Sodium Intake ◽  
Meta Analysis ◽  
Control Diet ◽  
Blood Pressure Reduction ◽  
Controlled Trials ◽  
Dash Diet ◽  
Randomized Controlled

ABSTRACT The Dietary Approaches to Stop Hypertension (DASH) diet is recognized as an effective dietary intervention to reduce blood pressure (BP). However, among randomized controlled trials (RCTs) investigating the DASH diet–mediated BP reduction, there are significant methodological and clinical differences. The purpose of this study was to comprehensively assess the DASH diet effect on BP in adults with and without hypertension, accounting for underlying methodological and clinical confounders. We systematically searched Medline and the Cochrane Collaboration Library databases and identified 30 RCTs (n = 5545 participants) that investigated the BP effects of the DASH diet compared with a control diet in hypertensive and nonhypertensive adults. Both random-effects and fixed-effect models were used to calculate the mean attained systolic BP (SBP) and diastolic BP (DBP) differences during follow-up. Subgroup and meta-regression analyses were also conducted. Compared with a control diet, the DASH diet reduced both SBP and DBP (difference in means: −3.2 mm Hg; 95% CI: −4.2, −2.3 mm Hg; P &lt; 0.001, and −2.5 mm Hg; 95% CI: −3.5, −1.5 mm Hg; P &lt; 0.001, respectively). Hypertension status did not modify the effect on BP reduction. The DASH diet compared with a control diet reduced SBP levels to a higher extent in trials with sodium intake &gt;2400 mg/d than in trials with sodium intake ≤2400 mg/d, whereas both SBP and DBP were reduced more in trials with mean age &lt;50 y than in trials of older participants. The quality of evidence was rated as moderate for both outcomes according to the Grading of Recommendations, Assessment, Development, and Evaluation approach. The adoption of the DASH diet was accompanied by significant BP reduction in adults with and without hypertension, although higher daily sodium intake and younger age enhanced the BP-lowering effect of the intervention. This meta-analysis was registered at www.crd.york.ac.uk/prospero as CRD42019128120.

scholarly journals A Hypocaloric High-Protein Diet Supplemented with β-Cryptoxanthin Improves Non-Alcoholic fatty liver disease: A randomized controlled trial

2020 ◽  
Author(s):  
Fatemeh Haidari ◽  
Abdollah Hojhabrimanesh ◽  
Bizhan Helli ◽  
Seyed-Saeed Seyedian ◽  
Kambiz Ahmadi-Angali ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Enzymes ◽  
Controlled Trial ◽  
Serum Levels ◽  
Alcoholic Fatty Liver ◽  
Randomized Controlled ◽  
And Control ◽  
Alcoholic Fatty Liver Disease

Abstract Background: Despite promising animal data, there is no randomized controlled trial (RCT) on the effects of high protein (HP)-diet and/or β-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD).Aims: Safety and efficacy assessment of a hypocaloric HP-diet supplemented with β-cryptoxanthin in NAFLD.Methods: Ninety-two Iranian NAFLD outpatients were recruited for this 12-week, single-center, parallel-group, double-blind RCT and randomized into 4 arms (n=23): HP-diet & β-cryptoxanthin (hypocaloric HP-diet + β-cryptoxanthin), HP-diet (hypocaloric HP-diet + placebo), β-cryptoxanthin (standard hypocaloric diet + β-cryptoxanthin), and control (standard hypocaloric diet + placebo). Serum levels of liver enzymes and grade of hepatic steatosis were assessed at baseline and study endpoint as outcome measures.Results: In the intention-to-treat population (N=92), HP-diet & β-cryptoxanthin group experienced greater 12-week reductions in serum levels of liver enzymes than control group (mean difference for alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase: -27.2, -7.2, -39.2, and -16.3 IU/L, respectively; all p<0.010). Clinical remission rate (achieving grade 0 hepatic steatosis) in HP-diet & β-cryptoxanthin group (82.6%) was also higher than other groups (13.0%, 17.4%, and 0.0% in HP-diet, β-cryptoxanthin, and control groups, respectively; p<0.001). Sixteen patients reported minor adverse events.Conclusion: A hypocaloric HP-diet supplemented with β-cryptoxanthin safely and efficaciously improves NAFLD.Trial registration number: This trial was registered at http://www.irct.ir as IRCT2017060210181N10.

scholarly journals A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Fatemeh Haidari ◽  
Abdollah Hojhabrimanesh ◽  
Bizhan Helli ◽  
Seyed-Saeed Seyedian ◽  
Kambiz Ahmadi-Angali ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Enzymes ◽  
Controlled Trial ◽  
Serum Levels ◽  
Alcoholic Fatty Liver ◽  
Randomized Controlled ◽  
And Control ◽  
Alcoholic Fatty Liver Disease

Abstract Background Despite promising animal data, there is no randomized controlled trial (RCT) on the effects of high protein (HP)-diet and/or β-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD). Aims: Safety and efficacy assessment of a hypocaloric HP-diet supplemented with β-cryptoxanthin in NAFLD. Methods Ninety-two Iranian NAFLD outpatients were recruited for this 12-week, single-center, parallel-group, double-blind RCT and randomized into 4 arms (n = 23): HP-diet and β-cryptoxanthin (hypocaloric HP-diet + β-cryptoxanthin), HP-diet (hypocaloric HP-diet + placebo), β-cryptoxanthin (standard hypocaloric diet + β-cryptoxanthin), and control (standard hypocaloric diet + placebo). Serum levels of liver enzymes and grade of hepatic steatosis were assessed at baseline and study endpoint as outcome measures. Results In the intention-to-treat population (N = 92), HP-diet and β-cryptoxanthin group experienced greater 12-week reductions in serum levels of liver enzymes than control group (mean difference for alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase: − 27.2, − 7.2, − 39.2, and − 16.3 IU/L, respectively; all p < 0.010). Clinical remission rate (achieving grade 0 hepatic steatosis) in HP-diet and β-cryptoxanthin group (82.6%) was also higher than other groups (13.0%, 17.4%, and 0.0% in HP-diet, β-cryptoxanthin, and control groups, respectively; p < 0.001). Sixteen patients reported minor adverse events. Conclusion A hypocaloric HP-diet supplemented with β-cryptoxanthin safely and efficaciously improves NAFLD. Trial registration number This trial was registered at https://www.irct.ir as IRCT2017060210181N10.

scholarly journals Clinical Utility of Serum Levels of Ubiquitin C-Terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury

Neurosurgery ◽  
2011 ◽  
Vol 70 (3) ◽  
pp. 666-675 ◽  
Author(s):  
Stefania Mondello ◽  
Akinyi Linnet ◽  
Andras Buki ◽  
Steven Robicsek ◽  
Andrea Gabrielli ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Clinical Utility ◽  
Injury Severity ◽  
Sandwich Elisa ◽  
Area Under The Curve ◽  
Serum Levels ◽  
Severe Tbi ◽  
Gcs Score ◽  
And Control

Abstract Background: Brain damage markers released in cerebrospinal fluid (CSF) and blood may provide valuable information about diagnosis and outcome prediction after traumatic brain injury (TBI). Objective: To examine the concentrations of ubiquitin C-terminal hydrolase-L1 (UCH-L1), a novel brain injury biomarker, in CSF and serum of severe TBI patients and their association with clinical characteristics and outcome. Methods: This case-control study enrolled 95 severe TBI subjects (Glasgow Coma Scale [GCS] score, 8). Using sensitive UCH-L1 sandwich ELISA, we studied the temporal profile of CSF and serum UCH-L1 levels over 7 days for severe TBI patients. Results: Comparison of serum and CSF levels of UCH-L1 in TBI patients and control subjects shows a robust and significant elevation of UCH-L1 in the acute phase and over the 7-day study period. Serum and CSF UCH-L1 receiver-operating characteristic curves further confirm strong specificity and selectivity for diagnosing severe TBI vs controls, with area under the curve values in serum and CSF statistically significant at all time points up to 24 hours (P &lt; .001). The first 12-hour levels of both serum and CSF UCH-L1 in patients with GCS score of 3 to 5 were also significantly higher than those with GCS score of 6 to 8. Furthermore, UCH-L1 levels in CSF and serum appear to distinguish severe TBI survivors from nonsurvivors within the study, with nonsurvivors having significantly higher and more persistent levels of serum and CSF UCH-L1. Cumulative serum UCH-L1 levels &gt; 5.22 ng/mL predicted death (odds ratio, 4.8). Conclusion: Serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome.

Role of Inflammatory Markers in Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment

2019 ◽  
Vol 15 (3) ◽  
pp. 247-253 ◽  
Author(s):  
Salwa S. Hosny ◽  
Ahmed M. Bahaaeldin ◽  
Mohamed S. Khater ◽  
Meram M. Bekhet ◽  
Hayam A. Hebah ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Elderly Patients ◽  
Vascular Disease ◽  
Plasma Glucose ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Hs Crp ◽  
And Control

<P>Background: Type 2 diabetes (T2DM) is a risk factor for Alzheimer’s disease and mild cognitive impairment. The etiology of cognitive impairment in people with T2DM is uncertain but, chronic hyperglycemia, cerebral micro vascular disease, severe hypoglycemia, and increased prevalence of macro vascular disease are implicated. </P><P> Objectives: To determine the serum levels of soluble vascular adhesion molecule (sVCAM-1) and highly sensitive C-reactive protein (hs-CRP) in elderly type 2 diabetics with mild cognitive impairment (MCI). Methods: Our study was conducted on 90 elderly subjects (aged 60 years old or more). They were divided into Group І, 30 patients with T2DM and mild cognitive impairment, group ІІ, 30 patients with T2DM without cognitive impairment and group III, 30 healthy subjects as a control group. They were subjected to history taking, full clinical examination, anthropometric measurement, the Addenbrooke’s Cognitive Examination III (ACE---III 2012), Fasting plasma glucose, 2 hours plasma glucose, HbA1c, lipid profile, protein/creatinine ratio, serum sVCAM-1 and hs-CRP. Results: Serum levels of sVCAM-1 in diabetic elderly patients with MCI were significantly higher (946.7 ± 162.01 ng/ml) than diabetic elderly patients without cognitive impairment (479.06 ± 65.27 ng/ml) and control (263.7 ± 72.05 ng/ml) with (P=0.002). Serum levels of Hs-CRP in diabetic elderly patients with MCI were significantly higher than as diabetic elderly patients without cognitive impairment and control with (P=0.005). Conclusion: Elderly diabetic patients with mild cognitive impairment have higher levels of soluble adhesion molecules and markers of low-grade systemic inflammation than other groups.</P>

Sign in / Sign up

Export Citation Format

Share Document